Clinical Trials on Multiple Sclerosis (Relapsing Remitting)

Total 3157 results

The Cleveland Clinic
University of Nottingham

Active, not recruiting

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom
Washington University School of Medicine
EMD Serono

Active, not recruiting

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis (CLOCK-MS)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Imcyse SA

Active, not recruiting

IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study (IMCY-MS-001)

Multiple Sclerosis, Relapsing-Remitting

Moldova, Republic of
Genentech, Inc.
Roche Pharma AG

Completed

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States, Canada, Belgium, Spain, France, Switzerland, Ukraine, Mexico, Germany, Bulgaria, United Kingdom, Romania, Czechia, Italy, Russian Federation, Serbia, Slovakia, Denmark
Biogen

Completed

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Germany
Rennes University Hospital
Institut National de Recherche en Informatique et en Automatique; Association... and other collaborators

Completed

Clinical Decision Support System (CADIMS) for MS Diagnostic (POCADIMS)

Multiple Sclerosis, Relapsing-Remitting

France
doaa mokhtar mahmoud

Completed

Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt

Multiple Sclerosis, Relapsing-Remitting

Egypt
University Hospital, Caen
Biogen

Completed

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort (RELEVANT)

Multiple Sclerosis, Relapsing-Remitting

France
Marquette University
University of Wisconsin, Milwaukee

Completed

Photobiomodulation Therapy in Persons With Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Northwestern University

Terminated

Maximizing Outcome of Multiple Sclerosis Transplantation (MOST)

Multiple Sclerosis, Relapsing-Remitting

United States
GeNeuro SA
Worldwide Clinical Trials; Institut de Recherches Internationales Servier; Les...

Completed

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS (CHANGE-MS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Ukraine, Germany, Spain, Bulgaria, Serbia, Russian Federation, Hungary, Italy, Croatia, Czechia, Estonia
Genentech, Inc.

Completed

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
Merck KGaA, Darmstadt, Germany

Terminated

A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS) (INCREASE)

Multiple Sclerosis, Relapsing-Remitting

Italy
University of Calgary
Alberta Innovates Health Solutions

Completed

Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Canada
Fondation Ophtalmologique Adolphe de Rothschild

Terminated

Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate (SURV-SEP)

Multiple Sclerosis, Relapsing-Remitting

France
Gazi University

Completed

The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Turkey
Hoffmann-La Roche

Completed

Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition

Multiple Sclerosis, Relapsing-Remitting

Spain
Imcyse SA

Terminated

A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis (SCLEROLYM)

Multiple Sclerosis, Relapsing-Remitting

Belgium
Genzyme, a Sanofi Company
Bayer

Completed

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Multiple Sclerosis, Relapsing-Remitting

Netherlands, Spain, Germany, Israel, United Kingdom, Canada, Australia, United States, Italy, Argentina, Croatia, Russian Federation, Poland, Czechia, Belgium, France, Brazil, Austria, Denmark, Mexico, Serbia, Sweden, Ukraine
Biogen
Elan Pharmaceuticals

Completed

Natalizumab Re-Initiation of Dosing

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
Universitätsklinikum Hamburg-Eppendorf

Completed

Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells (ETIMS)

Multiple Sclerosis, Relapsing-Remitting
Bayer

Completed

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS (ABOVE)

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
University of Aarhus
Aarhus University Hospital; Biogen

Completed

Multiple Sclerosis and Progressive Resistance Training

Multiple Sclerosis (Relapsing Remitting)

Denmark
Merck KGaA, Darmstadt, Germany
Merck A.E., Greece

Completed

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

Multiple Sclerosis, Relapsing-Remitting

Greece
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. (SMART)

Multiple Sclerosis, Relapsing-Remitting

Netherlands
Rennes University Hospital

Unknown

Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses (COPOUSEP)

Multiple Sclerosis, Relapsing-Remitting

France
Bayer

Completed

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron (START)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
McGill University

Completed

Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)

Multiple Sclerosis, Relapsing-Remitting

Canada
Bayer

Completed

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Multiple Sclerosis, Relapsing-Remitting

United States
Assistance Publique - Hôpitaux de Paris

Completed

Imaging of Intracerebral Inflammation in MS (INFLASEP)

Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive

France
Nottingham University Hospitals NHS Trust

Not yet recruiting

MS Relapses During COVID-19 Pandemic

Multiple Sclerosis | Covid19 | Relapsing Remitting Multiple Sclerosis
Friedemann Paul
Roche Pharma AG

Active, not recruiting

Sensitivity of Motor Assessment in MS - a Prospective Cohort Study (MOTOSENS)

Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive

Germany
Celgene

Not yet recruiting

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Universität Münster

Recruiting

Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis (CLAProMS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Hasselt University

Recruiting

Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Belgium
Bristol-Myers Squibb

Recruiting

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (SWITCH - ITA)

Multiple Sclerosis, Relapsing-Remitting

Italy
Amsterdam UMC, location VUmc

Recruiting

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis (BLOOMS)

Multiple Sclerosis, Relapsing-Remitting

Netherlands
Immunic AG

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-2)

Multiple Sclerosis, Relapsing-Remitting

Turkey, United States, India, United Kingdom, Bosnia and Herzegovina, Estonia, Poland, Romania, Serbia, Ukraine, Armenia, Peru
University of Alabama at Birmingham

Recruiting

Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Berkovich, Regina MD, PhD Inc.
Biogen; Cedars-Sinai Medical Center

Recruiting

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Riley Bove, MD

Recruiting

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (ReWRAP)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Completed

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Multiple Sclerosis, Relapsing-Remitting

United States, Spain, Canada, Australia, Germany, Italy, United Kingdom, Belgium, Netherlands, France, Israel
Asuman Kucukoner

Completed

Speech in Noise Discrimination Skills in Multiple Sclerosis Patients.

Multiple Sclerosis-Relapsing-Remitting

Turkey
Biogen

Terminated

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Hoffmann-La Roche

Completed

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Canada, United States
Rennes University Hospital

Active, not recruiting

Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis (MS-TRACTS)

Multiple Sclerosis, Relapsing-Remitting

France
Celgene

Completed

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Germany
Mapi Pharma Ltd.

Completed

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Multiple Sclerosis, Relapsing-Remitting

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Estonia, Georgia, Israel, Moldova, Republic of, Russian Federation, Ukraine
Uppsala University
Karolinska University Hospital; Sahlgrenska University Hospital, Sweden; University... and other collaborators

Completed

Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden (AutoMS-Swe)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Sweden
Biogen

Completed

Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP (TEC-ADHERE)

Multiple Sclerosis, Relapsing-Remitting

France

Clinical Trials on Multiple Sclerosis (Relapsing Remitting)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations